Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), and other diseases driven by dysregulated aldosterone, announced today that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference. The conference will take place in Las Vegas on May 14-16, 2024.
Mineralys Therapeutics is dedicated to developing medicines for hypertension, CKD, and other diseases driven by dysregulated aldosterone. Their lead product candidate, lorundrostat, is an orally administered aldosterone synthase inhibitor designed for cardiorenal conditions affected by dysregulated aldosterone. The company, based in Radnor, Pennsylvania, was founded by Catalys Pacific. For more information about Mineralys Therapeutics, please visit their website at https://mineralystx.com or follow them on LinkedIn and Twitter.
For investor relations inquiries, please contact investorrelations@mineralystx.com. For media relations, reach out to Tom Weible at Elixir Health Public Relations by phone at (1) 515-707-9678 or email at tweible@elixirhealthpr.com.
The fireside chat featuring Mineralys Therapeutics will be held on Wednesday, May 15